 | |
| Clinical data | |
|---|---|
| Trade names | Phenurone |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 22–25 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.519 |
| Chemical and physical data | |
| Formula | C9H10N2O2 |
| Molar mass | 178.191 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Phenacemide (INN, BAN) (brand name Phenurone), also known as phenylacetylurea, is an anticonvulsant of the ureide (acetylurea) class. It is a congener and ring-opened analogue of phenytoin (a hydantoin), and is structurally related to the barbiturates and to other hydantoins. Phenacemide was introduced in 1949 for the treatment of epilepsy, but was eventually withdrawn due to toxicity.
See also
External links
- Diseases Database (DDB): 34078
- MedlinePlus DrugInfo uspdi-202454
- Coker S (1986). "The use of phenacemide for intractable partial complex epilepsy in children". Pediatr Neurol. 2 (4): 230–2. doi:10.1016/0887-8994(86)90053-6. PMID 3508693.
- Coker S, Holmes E, Egel R (1987). "Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations". Neurology. 37 (12): 1861–6. doi:10.1212/wnl.37.12.1861. PMID 3683877. S2CID 219205208.